Alyftrek for Australians
Time is running out. We have until 28 May 2025 to show the Pharmaceutical Benefits Advisory Committee (PBAC) just how vital access to Alyftrek is for Australians living with cystic fibrosis.
Learn More
Meet Avery
Three Years Old. Two Stomas. One Fierce Fighter.
Donate Today
2024 Annual Report
The Cystic Fibrosis Australia Annual Report is now available
Read Here
Embracing Tomorrow
CF is the most common, life-limiting genetic condition affecting Australians.
Learn More

Cystic Fibrosis Australia (CFA) is the peak consumer body for people living with cystic fibrosis (CF).

We focus on collaborative programmes and research, funding partnerships and advocacy.

 

CF is a recessive genetic condition. It primarily affects the lungs and digestive system because of a malfunction in the exocrine system, responsible for producing saliva, sweat, tears and mucus

Get Involved

By supporting CFA you will be helping further research, development, collaboration and advocacy so that all Australians living with CF are represented at a national level and heard by Government and Health and Community sectors.

Numbers Speak

CF is a genetic condition, however, each person with CF is unique.

Over

Australians live with CF

There are over

Gene mutations

Average life expectancy

Years

A baby is born with CF every

Days

CF Research

CFA leads the national research program, the Australian Cystic Fibrosis Research Trust (ACFRT), by overseeing all administration requirements. The ACFRT is dedicated to the core objective of funding research into the treatment and cure of CF.

It is important to note that 100% of the funds raised or donated to the ACFRT are used to support research. 

Standards of Care

The first four chapters of the Standards of Care For Cystic Fibrosis have been published, with more to be added in the coming months. 

Need More Information?

If you have any questions, need more information, or would like to sign up to our regular newsletters, please contact us. 

Scroll to Top